FBR Capital reiterated an Outperform rating on Genocea Biosciences (NASDAQ: GNCA), and cut the price target to $17.00 (from $20.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Unusual 11 Mid-Day Movers 10/19: (WTW) (DHRM) (PDII) Upgraded; (GNCA) (GLDD) (ISH) LowerOctober 19, 2015 1:01 PM Genocea Biosciences (GNCA) PT Lowered to $15 at Needham & CompanyOctober 19, 2015 10:03 AM Pre-Open Stock Movers 10/19: (WTW) (HEB) (PMCS) Higher; (GNCA) (GLDD) (SCTY) (MS) Lower (more...)October 19, 2015 9:16 AM Genocea Biosciences (GNCA) Announces GEN-004 Phase 2a Results Not Statistically SignificantOctober 19, 2015 7:02 AM Genocea Announces Top-Line Results from Phase 2a Trial for Universal Pneumococcal Vaccine Candidate GEN-004October 19, 2015 7:00 AM Genocea Biosciences (GNCA) halted with news pendingOctober 19, 2015 6:57 AM